clinical

Articles

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.



FDA accepts resubmitted Xipere NDA from Bausch Health, Clearside

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Study results show the device offers an effective long-term option for patients.

Treating chronic uveitis with fluocinolone acetonide implants

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis 

Confirming uveitis treatment efficacy in study

Studies highlight the need for specialists and training programs focusing on the disease.

Why uveitis is a leading and underestimated cause of visual morbidity in patients

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

AAO 2020: Fingolimod for MS offers disease control with no development of uveitis

Videos

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

AAO 2020: Study confirms Phase III results for uveitis treatment

Chronic cases can be difficult for retina specialists; treatment is satisfying.

Noninfectious uveitis: Meeting the challenge

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Look for clues to simplify anterior uveitis diagnosis

Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action

Ongoing study evaluates sirolimus as therapeutic option for uveitis 

One biologic response modifier has indication for uveitis; several in development to gain FDA approval

Uveitis